Research Study Search Tool

Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?

Search Results: Treatment + Pancreatic Cancer (4 results)

Here are some research studies that may be enrolling patients like you. Please check with the study contact and your health care provider to confirm your eligibility and see if the study is right for you. Note, our search tool may not be comprehensive and additional research resources can be found here.

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

Treatment:
Pancreatic

Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy

This is a phase II clinical trial enrolling people with advanced (inoperable) pancreatic cancer who have a BRCA1, BRCA2 or PALB2 mutation to determine whether the PARP inhibitor, rucaparib, could be used as a maintenance therapy after at least 4 months of chemotherapy.

We will enroll patients who have received at least 4 months of platinum-based therapy such as FOLFIRINOX, FOLFOX or cisplatin + gemcitabine.  Patients will stop chemotherapy and will all start rucaparib, a pill that is taken twice a day. 

Visit the study website for more information.

 

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden

Treatment:
Breast
Ovarian
Pancreatic
Prostate

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden

This study is researching a combination of two immunotherapy drugs for advanced solid tumors that contain a tumor biomarker known as "High Tumor Mutation Burden" (TMB-H). The researchers are studying whether treatment  of these tumors with a combination of the drugs nivolumab plus ipilimumab is safe and effective compared with nivolumab alone. 

A Phase II Study to Evaluate the Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib in Patients with a BRCA or ATM Mutation

Treatment:
Breast
Ovarian
Pancreatic

A Phase II Study to Evaluate the Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib in Patients with a BRCA or ATM Mutation

This study is looking at how well two cancer drugs work together to treat certain advanced cancers. 

The researchers want to learn how safe and effective the combination of an immunotherapy (known as Avelumab) and a PARP inhibitor (known as Talazoparib) is for treating patients with locally advanced or metastatic solid tumors with a BRCA1, BRCA2, or ATM gene defect.

Chemotherapy/PARP Inhibitor Combination for Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Treatment:
Pancreatic

Chemotherapy/PARP Inhibitor Combination for Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

This clinical trial studies a combination of drugs to learn the best dose, side effects, and how well they work together for treating patients with pancreatic, colorectal, gastroesophageal, or biliary cancer that has spread to other places in the body. 

Additional Results on Clinicaltrials.gov: Treatment + Pancreatic Cancer

192 Results

Clinical Trial Official Title
NCT04193904 A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer
NCT01972919 MR Guided Dose Escalated RT + Concurrent Chemotherapy in Unresectable Pancreatic Cancer
NCT02128100 Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer
NCT03716531 Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients With Pancreatic Cancer With Vascular Involvement
NCT03492671 Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
NCT03104439 Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
NCT02598349 Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
NCT03599362 Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer
NCT02454140 Stereotactic Body Radiotherapy Dose Escalation in Pancreatic Cancer
NCT02427841 Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
NCT02207465 A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer
NCT03704662 Stereotactic Body Radiation Therapy or Conventionally Fractionated Concurrent Chemotherapy and Radiation Therapy Preoperatively for Resectable or Borderline Resectable Pancreatic Adenocarcinoma
NCT02599662 Intraoperative Radiation Therapy for Resectable Pancreas Cancer
NCT02337465 KV-CBCT and Ultrasound Imaging in Guiding Radiation Therapy in Patients With Prostate, Liver, or Pancreatic Cancer
NCT04106856 Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer (SHAPER)
NCT03991962 Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
NCT02648282 Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer
NCT02639026 Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
NCT03652428 Locally Advanced Pancreatic Cancer (LAPC) (GCC 1886)
NCT04161755 Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery
NCT03073785 Hypofractionated Stereotactic Body Radiation Therapy and Fluorouracil or Capecitabine With or Without Zoledronic Acid in Treating Patients With Locally Advanced Pancreatic Cancer
NCT03600623 Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer
NCT03885284 Study of Proton Therapy in Adjuvant Pancreatic Cancer
NCT02451982 Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab and Urelumab Trial for Surgically Resectable Pancreatic Cancer
NCT03536208 Biological Effect of Warfarin on Pancreatic Cancer
NCT02349867 Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer
NCT03536182 Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer
NCT03109041 Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
NCT01088789 A Trial of Boost Vaccinations of Pancreatic Tumor Cell Vaccine
NCT03161379 GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer
NCT03122106 Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
NCT04115254 Stereotactic Magnetic Resonance Guided Radiation Therapy
NCT02173353 Feasibility of Using Ultrasound to Track Respiration Motion
NCT03572283 Bethanechol Prior to Pancreatic Surgery
NCT03192462 TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer
NCT03621644 Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer
NCT03187951 PancFit: Multimodal Exercise During Preoperative Therapy for Pancreatic Cancer
NCT02515513 The Role of Muscle Cachexia in Pancreatic Cancer
NCT03322995 Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients With Localized Pancreatic Cancer
NCT03384238 Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
NCT03623984 Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers
NCT02843945 Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
NCT03723915 Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer
NCT03601923 Niraparib in Patients With Pancreatic Cancer
NCT03281382 Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer
NCT03323944 CAR T Cell Immunotherapy for Pancreatic Cancer
NCT03711890 Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer
NCT03523312 Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer
NCT03745794 Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery
NCT03340974 Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer
NCT04203641 L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer
NCT03469258 Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma
NCT03563248 Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
NCT03140670 Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy
NCT02902484 Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer
NCT03307564 Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer
NCT03970252 Nivolumab in Combination With Chemotherapy Before Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer
NCT02863783 EUS Fiducial for Pancreas Surgery
NCT02672917 Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies
NCT04008537 Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device
NCT03373188 VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
NCT03519308 A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Micoenvironment in Resectable Pancreatic Cancer
NCT02705196 LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
NCT03138720 Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
NCT02047474 Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
NCT03323489 Celiac Plexus Radio-Surgery for Pain Management
NCT04005690 Cobimetinib or Olaparib in Treating Patients With Resectable Pancreatic Cancer
NCT03699319 CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
NCT03257033 Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
NCT03798769 Supportive Oncology Care at Home for Patients With Pancreatic Cancer Receiving Preoperative FOLFIRINOX
NCT03977233 Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
NCT02757859 High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
NCT03006302 Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer
NCT02080221 BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
NCT03634332 Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC
NCT03086642 Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer
NCT03168737 18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients
NCT03095781 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
NCT03434678 Use of Epidurals Intraoperatively for Patients Undergoing Pancreas Resection
NCT03269994 Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?
NCT03899636 A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer
NCT02079740 Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
NCT02070705 DCE MRI in Patients With Pancreatic Cancer
NCT03856658 Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases
NCT02723331 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
NCT03644173 Personal Resilience Empowerment Program Study
NCT03147768 Laser Tissue Welding - Distal Pancreatectomy Sealing Study
NCT01365169 Post-op Wellness Program for Pancreatic Cancer Patients That Uses Patient Feedback and Real-time Provider Monitoring
NCT03948763 A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
NCT03257761 Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
NCT02677038 Olaparib in Treating Patients With Stage IV Pancreatic Cancer
NCT03454035 Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
NCT03425279 CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors
NCT03376659 Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
NCT03264404 Azacitidine and Pembrolizumab in Pancreatic Cancer
NCT02578732 FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
NCT03623464 RCT of Mobile Apps & FitBit v. Usual Care
NCT03552718 QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
NCT03336216 A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
NCT02446093 Neoadjuvant GMCI Plus Chemoradiation for Advanced Non-Metastatic Pancreatic Adenocarcinoma
NCT03435289 A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer
NCT03714555 Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine
NCT03649321 Chemotherapy With Nab-paclitaxel/Germcitabine/Cisplatin +/- BGB324 With Pancreatic Cancer
NCT03935893 Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
NCT03816358 Anetumab Ravtansine With Nivolumab, Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Mesothelin Positive Advanced Pancreatic Cancer
NCT03190941 Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
NCT02830724 Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT03745326 Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
NCT03190265 Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
NCT03883919 Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy
NCT03767582 Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
NCT02340117 Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
NCT03611309 Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members
NCT03703063 Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
NCT04098081 1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
NCT02908451 A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
NCT02905578 A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
NCT02671890 Disulfiram and Gemcitabine Hydrochloride in Treating Patients With Unresectable Solid Tumors or Metastatic Pancreatic Cancer
NCT03250273 A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
NCT01174121 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT03785210 Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
NCT04068896 Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
NCT03535727 A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
NCT03910387 Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
NCT03849469 A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
NCT03410030 Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)
NCT03153410 Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
NCT02451553 Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer
NCT03484299 Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
NCT03553004 Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial
NCT03825289 Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
NCT03727880 Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
NCT03752398 A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
NCT04147494 PET Biodistribution Study of 68Ga-PSMA-11 and 68Ga-FAPI-46
NCT03953235 A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens
NCT03576131 GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
NCT01845805 Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine, Abraxane, Gemcitabine)
NCT03404960 Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy
NCT03184870 A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors
NCT02433626 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies
NCT02897375 Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
NCT00720785 Natural Killer Cells and Bortezomib to Treat Cancer
NCT03682289 Phase II Trial of AZD6738 Alone and in Combination With Olaparib
NCT03127124 QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer
NCT03941093 Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Gemcitabine and Nab-paclitaxel) in Locally Advanced Pancreatic Cancer
NCT04180371 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT03512756 A Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer
NCT03086369 A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
NCT03878524 A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia
NCT03058289 A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
NCT03331562 A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer
NCT03412799 Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
NCT01351103 A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
NCT01676259 A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer
NCT02465060 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT03415854 Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)
NCT03854110 Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine
NCT03816163 A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
NCT03065062 Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
NCT03637491 A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors
NCT03193190 A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
NCT02826486 Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202)
NCT02744287 Use of Ligand-Inducible Autologous T Cells Engineered to Target PSCA on Tumor Cells in Selected Advanced Solid Tumors
NCT03126435 EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
NCT02921022 Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
NCT03043664 Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
NCT03784677 SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors
NCT02834013 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT03375320 Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
NCT03454451 CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
NCT03504423 Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas
NCT02595424 Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
NCT03368963 TAS102 in Combination With NAL-IRI in Advanced GI Cancers
NCT02791334 A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
NCT01954992 Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
NCT03841110 FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
NCT02983578 AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer
NCT03829436 TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced Cancers
NCT03829501 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer
NCT03678883 9-ING-41 in Patients With Advanced Cancers
NCT02498613 A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
NCT02632448 A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT03337087 Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
NCT03129139 A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
NCT04148937 A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
NCT03565445 A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors
NCT03077685 Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma
NCT01643460 Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts
NCT03736720 Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
NCT04171700 A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes
NCT03102320 Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors
NCT03884556 TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

FORCE:Facing Our Risk of Cancer Empowered